Xospata Drug Interactions

Effects of Other Drugs on Xospata: Concomitant use of Xospata with drugs that are strong inducers of CYP3A/P-gp (e.g., rifampin, phenytoin, St. John's Wort) should be avoided as they can decrease the plasma exposure of Xospata (see PHARMACOLOGY: Pharmacokinetics under Actions).
Concomitant use of Xospata with drugs that are strong inhibitors of CYP3A and/or P-gp (e.g., voriconazole, itraconazole, posaconazole, clarithromycin, erythromycin, captopril, carvedilol, ritonavir, azithromycin) should be used with caution as they can increase the plasma exposure of Xospata (see PHARMACOLOGY: Pharmacokinetics under Actions).
Effects of Xospata on Other Drugs: Based on in vitro data, Xospata may reduce the effects of drugs that target 5HT2B receptor or sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these drugs with Xospata unless use is considered essential for the care of the patient (see PHARMACOLOGY: Pharmacokinetics under Actions).
Xospata is an inhibitor of P-gp, breast cancer resistant protein (BCRP) and OCT1 in vitro. As Xospata may inhibit transporters at a therapeutic dose, caution is advised during coadministration of Xospata with substrates of P-gp (e.g., digoxin, dabigatran etexilate), BCRP (e.g., mitoxantrone, rosuvastatin) and OCT1 (e.g., metformin) (see PHARMACOLOGY: Pharmacokinetics under Actions).